Kiniksa Pharmaceuticals Ltd (KNSA)vsZoetis Inc (ZTS)
KNSA
Kiniksa Pharmaceuticals Ltd
$45.84
+2.00%
HEALTHCARE · Cap: $3.44B
ZTS
Zoetis Inc
$116.71
+0.67%
HEALTHCARE · Cap: $51.09B
Smart Verdict
WallStSmart Research — data-driven comparison
Zoetis Inc generates 1297% more annual revenue ($9.47B vs $677.56M). ZTS leads profitability with a 28.2% profit margin vs 8.7%. ZTS trades at a lower P/E of 19.3x. ZTS earns a higher WallStSmart Score of 64/100 (C+).
KNSA
Buy51
out of 100
Grade: C-
ZTS
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-28.1%
Fair Value
$35.10
Current Price
$45.84
$10.74 premium
Margin of Safety
-29.1%
Fair Value
$99.69
Current Price
$116.71
$17.02 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 65.0% year-over-year
Conservative balance sheet, low leverage
Every $100 of equity generates 66 in profit
Strong operational efficiency at 34.7%
Safe zone — low bankruptcy risk
Large-cap with strong market position
Keeps 28 of every $100 in revenue as profit
Areas to Watch
Premium valuation, high expectations priced in
Expensive relative to growth rate
Trading at 14.9x book value
3.0% revenue growth
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : KNSA
The strongest argument for KNSA centers on Revenue Growth, Debt/Equity. Revenue growth of 65.0% demonstrates continued momentum.
Bull Case : ZTS
The strongest argument for ZTS centers on Return on Equity, Operating Margin, Altman Z-Score. Profitability is solid with margins at 28.2% and operating margin at 34.7%.
Bear Case : KNSA
The primary concerns for KNSA are P/E Ratio. A P/E of 59.9x leaves little room for execution misses.
Bear Case : ZTS
The primary concerns for ZTS are PEG Ratio, Price/Book, Revenue Growth. Debt-to-equity of 2.85 is elevated, increasing financial risk.
Key Dynamics to Monitor
KNSA profiles as a hypergrowth stock while ZTS is a value play — different risk/reward profiles.
ZTS carries more volatility with a beta of 0.95 — expect wider price swings.
KNSA is growing revenue faster at 65.0% — sustainability is the question.
ZTS generates stronger free cash flow (732M), providing more financial flexibility.
Bottom Line
ZTS scores higher overall (64/100 vs 51/100), backed by strong 28.2% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Kiniksa Pharmaceuticals Ltd
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Kiniksa Pharmaceuticals Ltd. (KNSA) is an innovative biopharmaceutical company focused on developing transformative therapies to meet significant unmet medical needs. Its leading candidate, KPL-404, is a targeted monoclonal antibody designed to inhibit B and T lymphocyte activity, offering new therapeutic avenues for various autoimmune disorders. With a strong pipeline and a commitment to scientific excellence, Kiniksa is well-positioned for growth, supported by strategic collaborations and ongoing clinical trials. The company's efforts could potentially redefine treatment paradigms within the biopharmaceutical sector, making it an attractive investment opportunity for institutional investors.
Visit Website →Zoetis Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Zoetis Inc. is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?